Evidence map›Paper›PMID 27419235›Full record

ArticleScience advances2016

In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector.

Yi Li, Marie Beitelshees, Lei Fang, Andrew Hill, Mahmoud Kamal Ahmadi, Mingfu Chen, Bruce A Davidson, Paul Knight, Randall J Smith, Stelios T Andreadis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Non-invasive delivery strategies for biologics.Nature reviews. Drug discovery · 2019
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yi LiDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Marie BeitelsheesDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Lei FangDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Andrew HillAbcombi Biosciences Inc., Buffalo, NY 14260-4200, USA.
Mahmoud Kamal AhmadiDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Mingfu ChenDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.ORCID 0000-0002-0169-613X
Bruce A DavidsonDepartment of Anesthesiology, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.ORCID 0000-0001-8223-1870
Paul KnightDepartment of Anesthesiology, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Department of Microbiology and Immunology, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.ORCID 0000-0002-9201-3305
Randall J SmithDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Stelios T AndreadisDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY 14203, USA.
Anders P HakanssonDepartment of Microbiology and Immunology, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Division of Experimental Infection Medicine, Department of Laboratory Medicine, Lund University, Malmö SE-20502, Sweden.ORCID 0000-0002-2834-6009
Charles H JonesDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Abcombi Biosciences Inc., Buffalo, NY 14260-4200, USA.
Blaine A PfeiferDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.; Abcombi Biosciences Inc., Buffalo, NY 14260-4200, USA.

Funding

A Hybrid Bio-synthetic Vector Designed to Elicit Directed in vivo Immune ResponseR21AI117309 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PFEIFER, BLAINE A. · 2016 to 2017
$435k
A Hybrid Biomaterial-biological Vector for Antigen Presenting Cell Gene DeliveryR03AI088485 · NIAID · TUFTS UNIVERSITY MEDFORD · PI PFEIFER, BLAINE A. · 2010 to 2011
$145k
NIAID NIH HHS R03 AI088485NIAID NIH HHS R21 AI117309
6 · The paper itself

Abstract

The type and potency of an immune response provoked during vaccination will determine ultimate success in disease prevention. The basis for this response will be the design and implementation of antigen presentation to the immune system. Whereas direct antigen administration will elicit some form of immunological response, a more sophisticated approach would couple the antigen of interest to a vector capable of broad delivery formats and designed for heightened response. New antigens associated with pneumococcal disease virulence were used to test the delivery and adjuvant capabilities of a hybrid biological-biomaterial vector consisting of a bacterial core electrostatically coated with a cationic polymer. The hybrid design provides (i) passive and active targeting of antigen-presenting cells, (ii) natural and multicomponent adjuvant properties, (iii) dual intracellular delivery mechanisms, and (iv) a simple formulation mechanism. In addition, the hybrid format enables device-specific, or in situ, antigen production and consolidation via localization within the bacterial component of the vector. This capability eliminates the need for dedicated antigen production and purification before vaccination efforts while leveraging the aforementioned features of the overall delivery device. We present the first disease-specific utilization of the vector toward pneumococcal disease highlighted by improved immune responses and protective capabilities when tested against traditional vaccine formulations and a range of clinically relevant Streptococcus pneumoniae strains. More broadly, the results point to similar levels of success with other diseases that would benefit from the production, delivery, and efficacy capabilities offered by the hybrid vector.

Indexed as

Adjuvants, ImmunologicAnimalsAntigens, BacterialBacterial ProteinsBiocompatible MaterialsDisease Models, AnimalFemaleMiceNasopharynxPneumococcal InfectionsPneumococcal VaccinesPolymersStreptococcus pneumoniaeVaccines, SyntheticAdjuvants, ImmunologicAntigens, BacterialBacterial ProteinsBiocompatible MaterialsPneumococcal Vaccinespoly(beta-amino ester)PolymersVaccines, SyntheticAntigen deliverybiological vectorbiomaterialspneumococcal diseasevaccine

Identifiers

PMID27419235
PMCPMC4942325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.